Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong, Terrence N; Ramsingh, Giridharan; Young, Andrew L; Miller, Christopher A; Touma, Waseem; Welch, John S; Lamprecht, Tamara L; Shen, Dong; Hundal, Jasreet; Fulton, Robert S; Heath, Sharon; Baty, Jack D; Klco, Jeffery M; Ding, Li; Mardis, Elaine R; Westervelt, Peter; DiPersio, John F; Walter, Matthew J; Graubert, Timothy A; Ley, Timothy J; Druley, Todd; Link, Daniel C; Wilson, Richard K.
; 518(7540): 552-555, 2015 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-25487151
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
How One Thing Led to Another.
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
The origin and evolution of mutations in acute myeloid leukemia.
The cell of origin and the leukemia stem cell in acute myeloid leukemia.
The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
Hyperactivated mitophagy in hematopoietic stem cells.
Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation.